Prot #NU 23H06: A Phase II Multi-Center Open-Label Trial of Six Doses of Pembrolizumab Monotherapy Prior to Limited Chemotherapy as Front-Line Therapy for Patients with Classical Hodgkin Lymphoma, Including Elderly Patients

Project: Research project

Project Details

StatusActive
Effective start/end date1/29/241/29/27

Funding

  • Merck Sharp & Dohme LLC (Prot #NU 23H06)